(PRESS RELEASE) BERLIN, GERMANY — Dopavision, a clinical-stage company pioneering the development of digital therapeutics, announced the appointment of Dr. Dirk Sauer as chairman of the Company’s Advisory Board. Dirk Sauer brings an exceptional track record in the development of ophthalmic therapeutics and an extensive industry network to advance MyopiaX, Dopavision’s leading-edge digital therapeutic for childhood myopia control. MyopiaX is currently in clinical trials in Germany, Portugal, Spain, and Ireland.
Dirk Sauer is an expert in eye therapeutics development with long-standing global experience in ophthalmology and neuroscience. At Novartis Pharma, he successfully led numerous projects and teams during all phases of the drug development process and was, among others, responsible for the development of ophthalmology therapies to treat the wet form of macular degeneration. Furthermore, he led the company’s Ophthalmology Development Unit as Global Development Unit Head for more than nine years. During that time, he built a development portfolio in various ocular indications, spanning from small molecules to biologics, gene therapies, and digital therapeutics. His leadership included the development unit of the former Alcon Pharma franchise.
“Dirk brings extremely valuable knowledge in both research and product development,” said Mark Wuttke, CEO of Dopavision. “He is familiar with a wealth of indications affecting both back and front of the eye, the selection of the best approaches and the challenges of bringing them to market. He will be a great addition to our Advisory Board and will provide leadership for the entire R&D team.”
“I am really excited to chair Dopavision’s Advisory Board,” said Dr. Dirk Sauer. “The Company has developed an outstanding technology to combat childhood myopia, a very pressing global health problem. I am very happy to contribute to the success of this entirely new concept – a true digital approach to treat eye disease.”
